

MOLECULAR CANCER THERAPEUTICS

TABLE OF CONTENTS

HIGHLIGHTS

1045 Selected Articles from This Issue

MCT FIRST DISCLOSURES

1047 Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing Tumors

Juniper A. Scribner, Stuart W. Hicks, Kerstin W. Sinkevicius, Nicholas C. Yoder, Gundo Diedrich, Jennifer G. Brown, Jacquelynn Lucas, Megan E. Fuller, Thomas Son, Anahita Dastur, Jeff Hooley, Christopher Espelin, Marian Themeles, Francine Z. Chen, Ying Li, Michael Chiechi, Jenny Lee, Bhaswati Barat, Lusiana Widjaja, Sergey Gorlatov, James Tamura, Valentina Ciccarone, Olga Ab, Kerry A. McEachem, Scott Koenig, Eric H. Westin, Paul A. Moore, Thomas Chittenden, Richard J. Gregory, Ezio Bonvini, and Deryk Loo

1060 HJM-561, a Potent, Selective, and Orally Bioavailable EGFR PROTAC that Overcomes Osimertinib-Resistant EGFR Triple Mutations

Yong Du, Yongfeng Chen, Yuxia Wang, Jinju Chen, Xiaorong Lu, Li Zhang, Yan Li, Zhaofu Wang, Guozhong Ye, and George Zhang

REVIEW

1067 Novel Markers for Liquid Biopsies in Cancer Management: Circulating Platelets and Extracellular Vesicles

Sara Corvigno, Anna Maria Johnson, Kwong-Kwok Wong, Min Soon Cho, Vahid Afshar-Kharghan, David G. Menter, and Anil K. Sood

SMALL MOLECULE THERAPEUTICS

1076 A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor

Huadong Chen, Morgan E. Diolaiti, Patrick C. O'Leary, Ajda Rojc, Nevan J. Krogan, Minkyu Kim, and Alan Ashworth

1090 TOP1-DNA Trapping by Exatecan and Combination Therapy with ATR Inhibitor

Ukhyun Jo, Yasuhisa Murai, Keli K. Agama, Yilun Sun, Liton Kumar Saha, Xi Yang, Yasuhiro Arakawa, Sophia Gayle, Kelli Jones, Vishwas Paralkar, Ranjini K. Sundaram, Jinny Van Doorn, Juan C. Vasquez, Ranjit S. Bindra, Woo Suk Choi, and Yves Pommier

1103 Colchicine-Binding Site Agent CH-2-77 as a Potent Tubulin Inhibitor Suppressing Triple-Negative Breast Cancer

Shanshan Deng, Raisa I. Krutilina, Kelli L. Hartman, Hao Chen, Deanna N. Parke, Rui Wang, Foyez Mahmud, Dejian Ma, Pradeep B. Lukka, Bernd Meibohm, Tiffany N. Seagroves, Duane D. Miller, and Wei Li

1115 Niraparib Shows Superior Tissue Distribution and Efficacy in a Prostate Cancer Bone Metastasis Model Compared with Other PARP Inhibitors

Linda A. Snyder, Rajendra Damle, Shefali Patel, Jared Bohrer, Anna Fiorella, Jenny Driscoll, Rebecca Hawkins, Christopher F. Stratton, Carol D. Manning, Kanaka Tatikola, Volha Trypitsen, Kathryn Packman, and Rao N.V.S. Mamidi

1125 Luxeptinib (CG-806) Targets FLT3 and Clusters of Kinases Operative in Acute Myeloid Leukemia

William G. Rice, Stephen B. Howell, Hongying Zhang, Nasrin Rastgoo, Andrea Local, Stephen E. Kurtz, Pierrette Lo, Daniel Bottomly, Beth Wilmot, Shannon K. McWeeney, Brian J. Druker, and Jeffrey W. Tyner

1136 Targeted Radionuclide Therapy with Low and High-Dose Lutetium-177-Labeled Single Domain Antibodies Induces Distinct Immune Signatures in a Mouse Melanoma Model

Thomas Ertveldt, Lien De Beck, Kirsten De Ridder, Hanne Locy, Wout De Mey, Cleo Goyvaerts, Quentin Lecocq, Hannelore Ceuppens, Yannick De Vlaeminck, Robin Maximilian Awad, Marleen Keyaerts, Nick Devoogdt, Matthias D'Huyvetter, Karine Breckpot, and Ahmet Krasniqi

1149 Augmenting Experimental Gastric Cancer Activity of Irinotecan through Liposomal Formulation and Antiangiogenic Combination Therapy

Niranjan Awasthi, Margaret A. Schwarz, Changhua Zhang, Stephan G. Klinz, Florence Meyer-Losic, Benjamin Beaufils, Arunthathi Thiagalingam, and Roderich E. Schwarz

TABLE OF CONTENTS

- 1160** **Peptide PDHPS1 Inhibits Ovarian Cancer Growth through Disrupting YAP Signaling**
Xinxing Pan, Zhe Geng, Jingyun Li, Xingxing Li, Mi Zhang, Xusu Wang, Yu Cong, Ke Huang, Juan Xu, and Xuemei Jia

LARGE MOLECULE THERAPEUTICS

- 1171** **Preclinical Efficacy of BCMA-Directed CAR T Cells Incorporating a Novel D Domain Antigen Recognition Domain**
Janine M. Buonato, Justin P. Edwards, Liubov Zaritskaya, Alexandra R. Witter, Ankit Gupta, David W. LaFleur, David A. Tice, Laura K. Richman, and David M. Hilbert
- 1184** **Olfactory Receptor OR2H1 Is an Effective Target for CAR T Cells in Human Epithelial Tumors**
Alexandra L. Martin, Carmen M. Anadon, Subir Biswas, Jessica A. Mine, Katelyn F. Handley, Kyle K. Payne, Gunjan Mandal, Ricardo A. Chaurio, John J. Powers, Kimberly B. Sprenger, Kristen E. Rigolizzo, Patrick Innamarato, Carly M. Harro, Sumit Mehta, Bradford A. Perez, Robert M. Wenham, and Jose R. Conejo-Garcia
- 1195** **Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors**
Sakshi Tomar, Jingli Zhang, Manakamana Khanal, Jessica Hong, Abhilash Venugopalan, Qun Jiang, Manjitha Sengupta, Markku Miettinen, Nan Li, Ira Pastan, Mitchell Ho, and Raffit Hassan
- 1207** **Nonclinical Characterization of Bexmarilimab, a Clever-1-Targeting Antibody for Supporting Immune Defense Against Cancers**
Maija Hollmén, Mikael Maksimow, Jenna H. Rannikko, Matti K. Karvonen, Marita Vainio, Sirpa Jalkanen, Markku Jalkanen, and Jami Mandelin

COMPANION DIAGNOSTIC, PHARMACOGENOMIC, AND CANCER BIOMARKERS

- 1219** **Variable Mutation Expression in Human Cancers: A “Hide-and-Seek” Mechanism Linked to Differential MHC-I Presentation Dynamics**
Amélie Boichard and Razelle Kurzrock

TARGETING DRUG RESISTANCE

- 1227** **Overcoming Resistance to Anti-Nectin-4 Antibody-Drug Conjugate**
Olivier Cabaud, Ludovic Berger, Emerence Crompt, José Adélaïde, Pascal Finetti, Séverine Garnier, Arnaud Guille, Nadine Carbuccia, Anne Farina, Emilie Agavnian, Max Chaffanet, Anthony Gonçalves, Emmanuelle Charafe-Jauffret, Emilie Mamessier, Daniel Birnbaum, François Bertucci, and Marc Lopez
- 1236** **Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246-Sensitive Disease Subtype**
Anna N. Cvrljevic, Umar Butt, Kaisa Huhtinen, Tove J. Grönroos, Camilla Böckelman, Heini Lassus, Ralf Butzow, Caj Haglund, Katja Kaipio, Tiina Arsiola, Teemu D. Laajala, Denise C. Connolly, Ari Ristimäki, Olli Carpen, Jeroen Pouwels, and Jukka Westermarck

MODELS AND TECHNOLOGIES

- 1246** **A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors**
Juana Fernández-Rodríguez, Edgar Creus-Bachiller, Xiaohu Zhang, Maria Martínez-Iniesta, Sara Ortega-Bertran, Rajarshi Guha, Craig J. Thomas, Margaret R. Wallace, Cleofe Romagosa, Lourdes Salazar-Huayna, Karlyne M. Reilly, Jaishri O. Blakely, Jordi Serra-Musach, Miguel Angel Pujana, Eduard Serra, Alberto Villanueva, Marc Ferrer, and Conxi Lázaro

TABLE OF CONTENTS

ABOUT THE COVER

IMGC936 is an antibody drug conjugate targeting ADAM9, a member of the ADAM family of multifunctional, multidomain type 1 transmembrane proteins. In this issue, Scribner and colleagues describe the preclinical development of IMGC936, a high-affinity humanized antibody site-specifically conjugated to DM21-C, a next-generation linker-payload that combines a maytansinoid microtubule-disrupting payload with a stable tripeptide linker, at a drug antibody ratio of approximately 2.0. Additionally, the YTE mutation was introduced into the CH2 domain of the antibody Fc to maximize in vivo plasma half-life and exposure. Read the full article on page 1047.

doi: 10.1158/1535-7163.MCT-21-7-CVR

